0000000001189743

AUTHOR

W. Koenig

showing 7 related works from this author

Deep sub-threshold $K^\ast (892)^{\circ}$ production in collisions of Ar + KCl at 1.76 A GeV

2013

researchProduct

Deep sub-threshold K*(892)0 production in collisions of Ar + KCl at 1.76A GeV

2013

Results on the deep sub-threshold production of the short-lived hadronic resonance K*(892)0 are reported for collisions of Ar + KCl at 1.76A GeV beam energy, studied with the High Acceptance Di-Electron Spectrometer (HADES) at SIS18/GSI. The K*(892)0 production probability per central collision of \( P_{K^{*0}}=(4.4\pm 1.1 \pm 0.5)\times 10^{-4}\) and the K*(892)0/K0 ratio of \( P_{K^{*0}}/P_{K^0}=(1.9\pm 0.5\pm 0.3)\times 10^{-2}\) are determined at the lowest energy so far (i.e. deep below the threshold for the corresponding production in nucleon-nucleon collisions, \( \sqrt{s_{NN}}-\sqrt{s_{thr}}=-340\) MeV). The K*0/K0 ratio is compared with results of other experiments and with the pre…

PhysicsNuclear reactionNuclear and High Energy PhysicsMeson010308 nuclear & particles physicsBranching fractionHadron7. Clean energy01 natural sciencesHadronizationNuclear physics0103 physical sciencesProduction (computer science)Atomic physics010306 general physicsNuclear ExperimentEnergy (signal processing)Dimensionless quantity
researchProduct

WITHDRAWN: A scintillator based time-of-flight hodoscope with a new type of emitter follower divider

2004

PhysicsNuclear and High Energy PhysicsTime of flightOpticsHodoscopebusiness.industryCommon collectorScintillatorbusinessInstrumentationNuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment
researchProduct

Verification of Electromagnetic Calorimeter Concept for the HADES spectrometer

2015

The HADES spectrometer currently operating on the beam of SIS18 accelerator in GSI will be moved to a new position in the CBM cave of the future FAIR complex. Electromagnetic calorimeter (ECAL) will enable the HADES@FAIR experiment to measure data on neutral meson production in heavy ion collisions at the energy range of 2-10 A GeVon the beam of the new accelerator SIS100. Calorimeter will be based on 978 massive lead glass modules read out by photomultipliers and a novel front-end electronics. Secondary gamma beam with energies ranging from 81 MeV up to 1399 MeV from MAMI-C Mainz facility was used to verify selected technical solutions. Relative energy resolution was measured using modules…

PhysicsHistoryPhotomultiplierRange (particle radiation)SpectrometerMesonPhysics::Instrumentation and DetectorsComputer Science ApplicationsEducationCalorimeterNuclear physicsMeasuring instrumentPhysics::Accelerator PhysicsElectronicsNuclear ExperimentBeam (structure)Journal of Physics: Conference Series
researchProduct

pp and ππ intensity interferometry in collisions of Ar+KCl at 1.76A GeV

2011

Results on pp, π+π+, and π-π- intensity interferometry are reported for collisions of Ar+KCl at 1.76$A$~GeV beam energy, studied with the High Acceptance Di-Electron Spectrometer (HADES) at SIS18/GSI. The experimental correlation functions as a function of the relative momentum are compared to model calculations allowing the determination of the space-time extent of the corresponding emission sources. The π π source radii are found significantly larger than the pp emission radius. The present radii do well complement the source-size excitation functions of the collision system of size $A+A \simeq 40+40$. The pp source radius at fixed beam energy is found to increase linearly with the cube r…

Nuclear reactionPhysicsNuclear and High Energy Physics010308 nuclear & particles physicsHadronRadius[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]01 natural sciencesNuclear physicsMomentumPionPair productionCorrelation function0103 physical sciencesAtomic physics010306 general physicsNucleonNuclear Experiment
researchProduct

Electromagnetic Calorimeter for HADES Experiment

2014

Electromagnetic calorimeter (ECAL) is being developed to complement dilep- ton spectrometer HADES. ECAL will enable the HADES@FAIR experiment to mea- sure data on neutral meson production in heavy ion collisions at the energy range of 2-10 AGeV on the beam of future accelerator SIS100@FAIR. We will report results of the last beam test with quasi-monoenergetic photons carried out in MAMI facility at Jo- hannes Gutenberg Universitat Mainz.

PhysicsPhotonMeson productionSpectrometerPhysics::Instrumentation and Detectors010308 nuclear & particles physicsPhysicsQC1-999Nuclear Theory7. Clean energy01 natural sciencesNuclear physicsElectromagnetic calorimeter0103 physical sciencesPhysics::Accelerator Physicsddc:530Heavy ionNuclear Experiment010306 general physicsBeam (structure)EPJ Web of Conferences
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct